H
Hangzhou Xingcheng Biotechnology
Cell and gene therapy CDMO services
About Hangzhou Xingcheng Biotechnology
Hangzhou Xingcheng Biotechnology, operating as CoJourney, is a Contract Development and Manufacturing Organization (CDMO) that provides services for cell and gene therapy companies worldwide. The company offers end-to-end process development, cGMP manufacturing, analytical method development, quality control testing, and product release for plasmids, viral vectors, and mRNA. Its business model is centered on providing custom-tailored, high-purity manufacturing solutions from development to GMP production.
CoJourney was founded by CEO Lijun Wang, who leads a management team with extensive operational experience in the global cell and gene therapy manufacturing sector. The company operates state-of-the-art cGMP manufacturing facilities in Hangzhou, China, and a process development center in Philadelphia, PA. In July 2023, CoJourney secured $30 million in a Series A financing round led by Legend Capital, with participation from GL Ventures, Legend Star Investment Management, and Lake Bleu Capital. This funding was aimed at expanding its US organization and commercial manufacturing capabilities, including a new facility at Spring House Innovation Park in Montgomery County, Pennsylvania.
The company's core services utilize proprietary platform technologies, including a notable "Zero Chrom Plasmid Platform" which reportedly reduces costs by up to 70% and production time by 60% while ensuring high purity. CoJourney's facilities are equipped with large-scale disposable bioreactors and fermenters to handle both clinical and commercial scale production, compliant with FDA, EMA, and NMPA regulations. The company has served over 40 clients and has successfully manufactured products approved for global clinical trials, including treatments for Neurovascular Age-Related Macular Degeneration in the USA and Spinal Muscular Atrophy in China.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2023 | $28M | $110M | Kaitai Capital · LYFE Capital · BioTrack Capital · Legend Star | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Xingcheng Biotechnology is 560 monthly website visits, down 53.3% over the last three months. Hangzhou Xingcheng Biotechnology's team grew 40% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Xingcheng Biotechnology in the Hangzhou ecosystem
The Hangzhou Xingcheng Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
- KCKaitai Capital
LYFE Capital
BioTrack Capital
Legend Star
Legend Capital
Hillhouse Capital
TF Capital- K2K2VC
Lake Bleu Capital- LZLianrong Zhidao
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Xingcheng Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Xingcheng Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.